arrow
S

Sander W. Tas

University of Amsterdam
H指数:42
被引数:6,118

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trial

脾脏神经调控作为单一疗法或与生物制剂或靶向合成DMARDs联用治疗难治性类风湿关节炎(ConsiderRAte):一项随机、假对照、早期可行性试验

2026-08-010
OAAI
Interobserver variability in synovial tissue biopsy markers in Rheumatoid Arthritis: Results from OMERACT special interest group on synovial tissue biopsy

类风湿关节炎滑膜组织活检标志物的观察者间变异性:来自OMERACT滑膜组织活检特别兴趣小组的结果

2026-07-010
PRE
Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS-CoV-2 Vaccination

SARS-CoV-2疫苗接种后早期短暂出现的异质性活化B细胞亚群

2026-03-120
OA
SARS-CoV-2 mRNA Vaccination Leads to Transient Humoral and B Cell Bystander Responses in Adults

SARS-CoV-2 mRNA疫苗接种导致成人出现短暂的体液和B细胞旁观者反应

2026-01-010
OAAI
Evolution of SARS-CoV-2 antibody repertoire after successive mRNA vaccinations under immunosuppressive treatment

在免疫抑制治疗下,经多次mRNA疫苗接种后SARS-CoV-2抗体谱的演变

2025-03-010
PRE
A deep intronic splice-altering AIRE variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusion
2024-09-181
PRE
LONGITUDINAL ASSESSMENT OF BIOMARKERS IN NOBILITY, A RANDOMIZED, PHASE II CLINICAL TRIAL OF OBINUTUZUMAB FOR TREATMENT OF PROLIFERATIVE LUPUS NEPHRITIS

纵向评估生物标志物在NOBILITY中的研究,这是一项关于奥滨尤妥珠单抗治疗增殖性狼疮肾炎的随机、二期临床试验。

2024-06-010
PRE